rais pt
strong year-end sinc mid-novemb vs
nbi period stock posit newsflow six-
month extens adcirca patent mid-novemb tax reform bill pass
congress decemb event impact non-gaap ep estim
posit go forward increas pt model
trough year earn sale trough see exhibit believ
sales/earn number might conserv per thesi
return sales/earn growth post adcirca patent loss may
stock outperform due earn upgrad stay bullish
consensu assum sales/earn trough model
base histor rare diseas gener entryassum loss
treprostinil franchis remodulin tyvaso orenitram
remodulin pump tyvaso result orenitram sale resum growth
view trough growth potenti treprostinil
franchis differ materi consensu
manag believ grow tresprostinil franchis
beyond frame refer assum treprostinil franchis
sale par valuat get uplift earn
alon multipl expans heighten visibl could doubl
believ patient remodulin highli unlik
case biolog given treprostinil lipid molecul
well-control patient convert gener leav
new patient gener believ success remodulin pump
approv mop patient
estim commerci govern plan
pay patient remodulin/tyvaso payer
hundr patient drug drug take price
increas alon would argu payer littl bandwidth quibbl
remodulin gener tyvaso beyond
disappoint us fail execut major strateg prioriti
remodulin pump approv freedom-ev interim case
made catalyst outsid manag control believ
manag understand focus pois deliv strong
remodulin pump approv posit tyvaso freedom-
unit therapeut corpor
biotechnolog compani focus
develop commerci
unmet medic need patient
chronic life-threaten condit
address
analyst certif import disclosur see disclosur appendix
trade compress multipl peer group
believ street under-appreci strength
busi model strong experienc
manag team newli launch product pipelin
help bridg patent cliff get back growth
bullish
slow loss remodulin tyvaso flolan
dynam model losses/year
adcirca patent loss complet
orenitram freedom-ev studi posit final readout
tyvaso studi posit
orenitram hit sale
quarterli sale updat orenitram remodulin tyvaso
effect competitor uptravi
statu fda applic launch strategi remodulin
readout freedom-ev
competit updat actelion own
remodulin pump tyvaso/beraprost combin
product growth
tyvaso posit phase lead growth product post-
loe
orenitram reach sale
success addit indic treprostinil organ
transplant busi and/or oncolog mid-term two three
freedom-ev neg final readout
orenitram sale ramp slows/flatten orenitram
remodulin tyvaso gener loss greater anticip
loss orenitram ip prior patent expir beyond
arriv pt vs previou util composit valuat methodolog biotechnolog compani base forward
price-to-earnings multipl net present valu adjust non-gaap estim earn peer index nbi index expect
earn compound-annual-growth-rate growth next three five year base case ascrib multipl
equal peer group averag due risk loss exclus loe three lead product
start late wacc reflect increas visibl product sale
downsid risk faster eros remodulin tyvaso adcirca sale expect gener entrant prior
time-frame heighten competit orenitram achiev blockbust statu greater sale next decad
unit statement million product total product adj research adj sell gener estim loss contingency- adj total oper oper interest expense- interest total expens incom report incom continu adj effect incom tax report incom continu incom discontinu operations- adj net dilut dilut share comp sale outperform
stock price compani mention report
